1. The greatest risk factor for developing or experiencing a relapse of schizophrenia is which of the following?

2. Which of the following clinical outcomes have been noted to improve with the use of long-acting injectable antipsychotics?

3. Long-acting injectable antipsychotics are more likely to demonstrate improved efficacy over oral formulations in what type of clinical trial design?

4. In a retrospective design clinical trial by Bera et al, 2014, investigators found that that Medicaid patients treated for schizophrenia with long-acting injectable antipsychotics had fewer schizophrenia related hospitalizations and ___________________.

5. In a clinical trial by Smeraldi et al, 2013, investigators compared schizophrenic patients treated for up to two years with risperidone long-acting injectable and oral quetiapine and determined that there was no difference in the amount of time in sustained remission; however, more patients treated with risperidone long-acting _______________.

6. Risk factors for problem adherence include which of the following?

7. Most clinical treatment guidelines suggest that long-acting injectable antipsychotics be considered in cases where medication adherence is a concern; however, clinicians are not particularly strong at identifying those patients and it is estimated that less than ______% of patients with known adherence issues actually receive them.

8. Results from the Electronic Schizophrenia Treatment Adherence Registry showed that after two years patients demonstrated greater improvement on what two scales?

9. Early treatment intervention in the treatment of schizophrenia is proposed to be advantageous and may actually serve to alter disease state progression by promoting _____________.

10. Shorter duration, randomized controlled trials comparing long-acting injectable antipsychotics and oral antipsychotics have not consistently demonstrated a clinically effective advantage for long-acting injectables because of which of the following?

« Return to Activity